Article Text
Abstract
Purpose This study investigates the clinical impact of electronic patient-reported outcome (ePRO) monitoring apps/web interfaces, aimed at symptom-management, in cancer patients undergoing outpatient systemic antineoplastic treatment. Additionally, it explores the advantages offered by these applications, including their functionalities and healthcare team-initiated follow-up programmes.
Methods A systematic literature review was conducted using a predefined search strategy in MEDLINE. Inclusion criteria encompassed primary studies assessing symptom burden through at-home ePRO surveys in adult cancer patients receiving outpatient systemic antineoplastic treatment, whenever health outcomes were evaluated. Exclusion criteria excluded telemedicine-based interventions other than ePRO questionnaires and non-primary articles or study protocols. To evaluate the potential bias in the included studies, an exhaustive quality assessment was conducted, as an additional inclusion filter.
Results Among 246 identified articles, 227 were excluded for non-compliance with inclusion/exclusion criteria. Of the remaining 19 articles, only eight met the rigorous validity assessment and were included for detailed examination and data extraction, presented in attached tables.
Conclusion This review provides compelling evidence of ePRO monitoring’s positive clinical impact across diverse cancer settings, encompassing various cancer types, including early and metastatic stages. These systems are crucial in enabling timely interventions and reducing communication barriers, among other functionalities. While areas for future ePRO innovation are identified, the primary limitation lies in comparing clinical outcomes of reviewed articles, due to scale variability and study population heterogeneity. To conclude, our results reaffirm the transformative potential of ePRO apps in oncology and their pivotal role in shaping the future of cancer care.
- Patient Reported Outcomes
- Adverse Drug Reaction Reporting Systems
- Antineoplastic agents
- MEDICAL ONCOLOGY
- Quality of Life
- Outcome Assessment, Health Care
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information. As this study is a systematic review, no new data were generated or analysed. All data used in this review are publicly available in the cited sources, and the comprehensive list of references is provided in the manuscript. The authors confirm that they had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Statistics from Altmetric.com
- Patient Reported Outcomes
- Adverse Drug Reaction Reporting Systems
- Antineoplastic agents
- MEDICAL ONCOLOGY
- Quality of Life
- Outcome Assessment, Health Care
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information. As this study is a systematic review, no new data were generated or analysed. All data used in this review are publicly available in the cited sources, and the comprehensive list of references is provided in the manuscript. The authors confirm that they had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.